Avenue Therapeutics Inc. has reported its financial results for the three months ending March 31, 2025. The company experienced an operating loss of $1.905 million, compared to a larger loss of $3.708 million during the same period in 2024. Operating expenses were impacted by a decline in research and development costs, which decreased to $411,000 from $2.392 million in the previous year. General and administrative expenses increased slightly to $1.494 million from $1.316 million. Additionally, the company recorded other income, including an interest income of $32,000 compared to $49,000 in the previous year, and a change in the fair value of warrant liabilities resulting in an income of $15,000 compared to a loss of $116,000 last year. A notable update in Avenue Therapeutics' business operations is the termination and transfer agreement with AnnJi, which was finalized on April 24, 2025. Further details about this agreement are available in Note 3 of their financial statement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.